Literature DB >> 30307757

Type 2 diabetes with hypertensive patients results in changes to features of adipocytokines: Leptin, Irisin, LGR4, and Sfrp5.

Baoxin Li1,2, Qi Yao1, Shuqin Guo1, Shuang Ma1, Yuehua Dong1, Huanhuan Xin1, He Wang1, Lifang Liu1, Wenlong Chang1, Yunliang Zhang1.   

Abstract

The incidence of hypertension and diabetes is increasing, it is reported that adipocytokines might be involved in the pathogenesis of diabetes and hypertension. We aimed to investigate the features of adipocytokines, included of Leptin, Irisin, LGR4, and Sfrp5 in type 2 diabetes mellitus (T2DM) patients with hypertension, simultaneously analyzed the connection of the alteration of adipocytokines with blood pressure and glucose. 424 patients with T2DM and 90 healthy subjects were included in the study. The patients with T2DM were divided into 4 groups based on the blood pressure. The levels of adipocytokines (Leptin, Irisin, LGR4, and Sfrp5) were determined by enzyme-linked immunosorbent assay (ELISA). Significantly higher levels of Leptin and lower levels of Irisin, LGR4 and Sfrp5 were seen in patients with diabetes compared with non-diabetes (P < 0.05), the mean values of Leptin level was ascending and Irisin, LGR4, and Sfrp5 levels were declining with promoting of blood pressure in hypertension as compared to the non-hypertension with diabetic patients. Multiple stepwise linear regression analysis showed that the concentrations of Leptin, Irisin, Sfrp5, and LGR4 were found to be closely associated with the control of blood pressure and glucose.
Conclusion: Four adipocytokines might play different roles and closely relate to the occurrence and development of diabetes and hypertension.

Entities:  

Keywords:  Diabetes; Irisin; LGR4; Leptin; Sfrp5; hypertension

Mesh:

Substances:

Year:  2018        PMID: 30307757     DOI: 10.1080/10641963.2018.1529779

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  7 in total

Review 1.  LGR4, a G Protein-Coupled Receptor With a Systemic Role: From Development to Metabolic Regulation.

Authors:  Joanna Filipowska; Nagesha G Kondegowda; Nancy Leon-Rivera; Sangeeta Dhawan; Rupangi C Vasavada
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-30       Impact factor: 6.055

2.  Fibronectin type III domain-containing 5 in cardiovascular and metabolic diseases: a promising biomarker and therapeutic target.

Authors:  Xin Zhang; Can Hu; Hai-Ming Wu; Zhen-Guo Ma; Qi-Zhu Tang
Journal:  Acta Pharmacol Sin       Date:  2020-11-19       Impact factor: 7.169

Review 3.  The Role of LGR4 (GPR48) in Normal and Cancer Processes.

Authors:  Alejandro Ordaz-Ramos; Victor Hugo Rosales-Gallegos; Jorge Melendez-Zajgla; Vilma Maldonado; Karla Vazquez-Santillan
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

4.  Altered features of neurotransmitters: NPY, α-MSH, and AgRP in type 2 diabetic patients with hypertension.

Authors:  Baoxin Li; Shuang Ma; Shuqin Guo; Na Li; Dandan Liu; He Wang; Na Zhai; Yunliang Zhang
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

5.  Serum protein signature of coronary artery disease in type 2 diabetes mellitus.

Authors:  Ramu Adela; Podduturu Naveen Chander Reddy; Tarini Shankar Ghosh; Suruchi Aggarwal; Amit Kumar Yadav; Bhabatosh Das; Sanjay K Banerjee
Journal:  J Transl Med       Date:  2019-01-24       Impact factor: 5.531

6.  Correlation Between Circulating Levels of Secreted Frizzled-Related Protein 5 and Type 2 Diabetic Patients and Subjects with Impaired-Glucose Regulation.

Authors:  Xiaoyan He; Huijuan Ma
Journal:  Diabetes Metab Syndr Obes       Date:  2020-04-22       Impact factor: 3.168

Review 7.  Emerging Roles for LGR4 in Organ Development, Energy Metabolism and Carcinogenesis.

Authors:  Linlin Yang; Jing Wang; Xiaodi Gong; Qiong Fan; Xiaoming Yang; Yunxia Cui; Xiaoyan Gao; Lijuan Li; Xiao Sun; Yuhong Li; Yudong Wang
Journal:  Front Genet       Date:  2022-01-24       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.